PDCD1 and hepatocellular carcinoma: In the future, we will design prospective studies with a longer follow-up and a larger sample size to verify the role of 18F-FDG PET in predicting pathological response and prognosis of unresectable HCC patients after treated by Lenvatinib in combination with PD-1 inhibitors as conversion therapy.